West Health



Civica aims to launch low-cost insulin in U.S. by 2024

Non-profit drugmaker Civica said on Thursday it expects to launch lower-cost versions of insulin in the United States by 2024, to help diabetic patients struggling with high prices for the life-sustaining medicine.

Nonprofit Civica goes after insulin prices in a big way, prepping for $30 vials by 2024

And that’s just what nonprofit generic drugmaker Civica is looking to do, with plans to manufacture and market three of the most common forms of insulin: glargine, lispro and aspart. Perhaps most importantly, the company says it plans to set the price of each insulin to the consumer at no more than $30 per vial and no more than $55 for a box of five pen cartridges.

US Covid Death Rate Marks ‘Dark Side of American Exceptionalism’

According to a study released in December by West Health and Gallup, 30% of U.S. adults reported skipping treatment for a health problem in the prior three months and nearly 60% said the pandemic heightened their concerns about healthcare costs.

Part D Plans Put More Generics On Non-Preferred Tiers

Sean Dickson, director of health policy for West Health, said the report doesn’t say how often brands are preferred over direct generic competitors so it’s not clear what proportion of generics are in non-generic tiers due to competition from other generics in the same class and not competition from brands.